Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Ulixacaltamide

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Praxis Precision Medicines Gets FDA Breakthrough Status
    Praxis Precision Medicines Gets FDA Breakthrough Status

    29 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/29/3210888/0/en/Praxis-Precision-Medicines-Announces-the-FDA-Has-Granted-Breakthrough-Therapy-Designation-for-Ulixacaltamide-HCl-in-Essential-Tremor.html

    GLOBENEWSWIRE
    29 Dec 2025
    Share Share
    FDA Clears Ulixacaltamide Pre-NDA for Essential Tremor
    FDA Clears Ulixacaltamide Pre-NDA for Essential Tremor

    04 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/04/3200309/0/en/Praxis-Precision-Medicines-Announces-Positive-Pre-NDA-Meeting-with-FDA-for-Ulixacaltamide-in-Essential-Tremor.html

    GLOBENEWSWIRE
    04 Dec 2025
    Share Share
    Praxis Precision Medicines to Participate in Fireside Chat
    Praxis Precision Medicines to Participate in Fireside Chat

    20 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/20/3192368/0/en/Praxis-Precision-Medicines-to-Participate-in-Upcoming-Fireside-Chat.html

    GLOBENEWSWIRE
    20 Nov 2025
    Share Share
    Praxis Precision Medicines Reports Positive Phase 3 Results
    Praxis Precision Medicines Reports Positive Phase 3 Results

    16 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/16/3167786/0/en/Praxis-Precision-Medicines-Announces-Positive-Topline-Results-from-Two-Pivotal-Phase-3-Studies-of-Ulixacaltamide-HCl-in-the-Essential3-Program-for-Essential-Tremor.html

    GLOBENEWSWIRE
    16 Oct 2025
    Share Share
    Praxis Precision Medicines Reports Q2 2024 Results And Corporate Update
    Praxis Precision Medicines Reports Q2 2024 Results And Corporate Update

    13 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/13/2929048/0/en/Praxis-Precision-Medicines-Provides-Corporate-Update-and-Reports-Second-Quarter-2024-Financial-Results.html

    GLOBENEWSWIRE
    13 Aug 2024
    Share Share
    Praxis At AAN On Ulixacaltamide
    Praxis At AAN On Ulixacaltamide

    12 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/12/2862133/0/en/Praxis-Precision-Medicines-to-Present-on-Ulixacaltamide-at-the-American-Academy-of-Neurology-2024-Annual-Meeting.html

    GLOBENEWSWIRE
    12 Apr 2024
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.